Trials / Unknown
UnknownNCT03113058
"Treatment of Active HBV With γδT Cells" Clinical Trial Protocol
"Treatment of HBeAg-positive Chronic Hepatitis B With γδT Cells" Clinical Trial Protocol
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Jinan University Guangzhou · Academic / Other
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and anti-HBV efficacy of γδT cells.
Detailed description
In this clinical trial, we will thoroughly evaluate the safety of in vitro expanded γδT cells, including allogeneic originated γδT cells, in clinical treatment of active HBV. At the same time, we will carefully and thoroughly examine and evaluate the clinical efficacy of γδT cells against active HBV, including lowering speed of DNA copy number, and the transferring rate of HBeAg from positive to negative.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | Adoptive transfer of γδT cells | Patients are treated via intravenous infusion of in vitro-activated allogeneic γδ Tcells every two weeks, 12 times in total (6 months). |
Timeline
- Start date
- 2017-05-02
- Primary completion
- 2018-10-05
- Completion
- 2018-11-01
- First posted
- 2017-04-13
- Last updated
- 2017-04-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03113058. Inclusion in this directory is not an endorsement.